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Th e genomic era has raised the possibility of major 
changes in the design, conduct, and even the existence of 
randomized trials as we know them [1­3]. Randomized 
trials are often seen as a slow, laborious, expensive, and 
diffi  cult step in the translational process and are 
associated with a high attrition rate for drugs. Indeed, 
most tests that are in use for the screening, diagnosis, 
prognosis, monitoring or management of patients have 
never been scrutinized by a randomized trial. Th is has 
largely been due to a failure to realize that tests can do as 
much harm and as much good as drugs or devices; thus, a 
rigorous appraisal of their clinical utility, including both 
the possible benefi ts and the possible harms, is necessary. 
Moreover, numerous new omics­based tests are continu­
ally being proposed, especially in the context of targeted 
preventive or therapeutic interventions. Given rapid 
develop ment of these new biomarkers, can we make ran­
dom ized trials more adaptable to a changing land scape? 
Furthermore, do we still need randomized trials at all? 
Our answers to these two questions are: yes, to some 
extent; and yes, defi nitely. We will explain our reasoning 
in this article.
Revolutionizing randomized trials in the 
genomic era
Genomic applications in medicine are highly diverse. 
Th ey range from diagnostic and carrier tests for many 
rare Mendelian conditions to complex biomarkers that 
inform preventive or therapeutic interventions. One 
relatively new area is the explicit linkage of a treatment 
and a companion diagnostic test (a molecular assay to 
indicate the likelihood of a patient responding to this 
specifi c treatment or reacting adversely). With this in 
mind, at least three types of potentially informative 
designs are available for the conduct of omics­informed 
clinical trials. Th e fi rst is the use of enrichment strategies, 
in which participants are selected for enrollment on the 
basis of a validated predictive tool to ensure the selection 
of those who are likely to have the best response rates 
(this approach is used to test biologically targeted thera­
pies) [1,2]. Th e second design makes use of surrogate 
markers (for example, a protein, metabolic, epigenetic, or 
other marker), especially validated markers, to conduct 
trials with a smaller sample size and a shorter follow­up 
period than traditional trials require. Th e third design 
incorporates a range of adaptive designs so that the trial 
can be optimized and modifi ed as it progresses. Various 
aspects can be altered, such as the inclusion and 
exclusion criteria and sample size, the data collection 
processes, and even the defi nitions of the endpoints and 
types of analyses. Th is fl exible approach would address 
the expectation that new information or discoveries will 
accumulate at such a rapid pace that external information 
could aff ect the conduct of trials midstream and could 
thus eff ectively guide their modifi cation. Trials could 
then be completed faster and might yield larger treatment 
eff ects and more defi nitive answers.
Despite these expectations of how genomic discoveries 
will alter clinical trials, omics research to date has not 
had the major clinical potential that was heralded. For 
example, despite decades of pharmacogenetics research, 
only a limited number of genetic variants have been 
robustly documented (at a genome­wide signifi cance 
level) as being associated with drug­related outcomes. Of 
the several thousand genetic associations that have been 
validated by genome­wide association studies (GWAS), 
few pertain to pharmacogenetics, and far fewer have the 
large eff ect sizes that would make them readily action­
able. In the 50 most recent GWAS that were indexed in 
the National Human Genome Research Institute GWAS 
catalog as of 28 February 2013 [4], only 3 of the 290 well­
validated variants (with P < 5 × 10­8) pertain to pharmaco­
genetics, and all 3 have small eff ect sizes that are unlikely 
to be useful in clinical practice.
Th e US Food and Drug Administration records 119 
pharmaco genetic associations that are listed on drug 
labels [5]. Only four, however, pertain to a clear require­
ment or a strong recommendation for genetic testing (for © 2010 BioMed Central Ltd
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example, cetuximab (EGFR), trastuzumab (HER2), mara­
viroc (CCR5), and dasatinib (BCR-ABL)). For the other 
associations, few randomized trials have proved the 
clinical utility of routine genetic tests; an exception is 
HLA-B*5701 testing to assess the suitability of treatment 
with abacavir [6]. In several additional cases, there is 
some supporting evidence from randomized trials, but 
this is based on surrogate outcomes: for example, 
CYP2C19 testing for patients to be treated with clopido­
grel, in which the main outcome assessed was platelet 
reactivity rather than major bleeding [7]. Most pharma­
co genetic associations listed on drug labels have not had 
their utility tested in clinical trials.
Many other markers, in diverse omics fields, lack even 
proper validation at the association level. It makes little 
sense to pursue and incorporate non­validated markers 
or non­validated molecular signatures in clinical trials. 
Standards for reproducible research need to be strength­
ened [8]. As to adaptive confirmatory trials, they remain 
mostly theoretical constructs. We lack examples of newly 
arising genomic information leading to an adaptation of 
the design of already ongoing large trials with major 
impact on their eventual success. Unjustified adaptations 
can end up being indistinguishable from spurious 
manipulations of the data collection and analysis plans.
Getting rid of randomized trials in the genomic era?
A common complaint is that clinical trials are too large 
and expensive to be practical and, instead, one could wish 
that omics research would make these trials more 
efficient or even replace them. The reality is different. 
Even for blockbuster drugs, randomized trials are rarely 
large enough to demonstrate conclusively benefits for 
major clinical outcomes and death [9]. Usually, informa­
tion is fragmented across many small or modest­sized 
trials, with selective publication and reporting. Rational i­
z ing the agenda of traditional randomized trials mostly 
requires common sense, not fancy omics. For example, 
designing several large, pivotal trials with reliable 
measurements and clinically relevant outcomes may yield 
more reliable information and at a lower cost than 
traditional randomized trials or trials incorporating 
expensive omics tests. Conversely, the most expensive 
part of many grant applications that propose to run 
clinical trials is the exploratory analysis with the latest 
crop of non­validated biomarkers.
One may argue that perhaps randomized trials could 
be skipped, especially when it comes to appraising all of 
the new omics tools and technologies. There are so many 
new tests that it is expensive to assess them with 
randomized trials. Moreover, these tools are constantly 
evolving; thus, if one genomic risk score is tested now, 
this score will alter or evolve while the trial is being 
conducted. Alternatively, perhaps other types of designs, 
such as studies with just one participant (n­of­1 studies) 
[3] are more commensurate with personalized medicine. 
These arguments can only go so far. The prostate­specific 
antigen (PSA) test, for example, was widely overused, and 
it took decades of debate and millions of misdiagnosed 
and mistreated patients before extirpating its un warranted 
routine use from clinical practice guidelines. Genomic 
tools can yield numerous biomarkers, all of which could 
fail in clinical use much like PSA. We agree that the 
targets for evaluation in randomized trials need to be 
chosen wisely and, indeed, some tests will evolve; there­
fore, the trials that are conducted will primarily be proof­
of­concept experiments. N­of­1 designs have value [3], 
but it is difficult to envisage that they could substitute for 
traditional randomized trials to answer most questions.
Most of the emerging genomic information that is 
meandering its way toward health applications is still 
either non­validated noise [10] or true signals with 
validated small effects, which are not suitable for applying 
to clinical practice. For the relatively few discoveries that 
represent more than noise or mere curiosities, random­
ized trials are indispensable to find out what they can 
really achieve. Novel trial designs are worth exploring the 
use of some types of omics information, and modeling, 
observational, and other non­randomized comparative 
effectiveness research might be useful in some cases. 
Nonetheless, such approaches will not eliminate the need 
for solid evidence from traditional randomized trials of 
the type that have been known for over 60 years but have 
rarely been performed and reported properly.
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